Intentional Mixture Of Two Or More Micro-organisms, Cells, Or Viruses Of Different Genera Patents (Class 424/93.3)
-
Patent number: 8318151Abstract: The present invention generally relates to the field of weight management and obesity. In particular the present invention relates to the use of probiotics in combination with prebiotics to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus rhamnosus NCC 4007 in combination with a specific probiotic mixture for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.Type: GrantFiled: February 4, 2010Date of Patent: November 27, 2012Assignee: Nestec S.A.Inventors: Christian Darimont-Nicolau, David Philippe, Catherine Mace, Fabrizio Arigoni
-
Patent number: 8318150Abstract: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to support weight management and to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus rhamnosus CNCM I-4096 for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.Type: GrantFiled: February 4, 2010Date of Patent: November 27, 2012Assignee: Nestec S.A.Inventors: Fabrizio Arigoni, Christian Darimont-Nicolau, Catherine Mace
-
Publication number: 20120294833Abstract: The present invention relates to novel strains of lactic acid bacteria, Lactobacillus plantarum subsp. plantarum PM-A0087 deposited as NRRL accession number B-50523, Bifidobacterium longum PM-A0101 deposited as NRRL accession number B-50525, and Bifidobacterium bifidum PM-A0218 deposited as NRRL accession number B-50524.Type: ApplicationFiled: May 14, 2012Publication date: November 22, 2012Applicant: PROMD BIOTECH. CO., LTD.Inventors: WEI-CHIH SU, KUANG-CHIH LEE, HSIANG-LING CHEN, HSIAO-LI WU
-
Patent number: 8309073Abstract: The invention relates to a probiotic combination comprising different combinations of lactobacilli, propionic acid bacteria and/or bifidobacteria. The probiotics are preferably combined with a suitable prebiotic to form a synbiotic. The combination of the invention can be consumed as such or combined with a suitable foodstuff or pharmaceutical product, and it is therapeutically useful for example for stimulating the immune system and for general health improvement.Type: GrantFiled: January 17, 2002Date of Patent: November 13, 2012Assignee: Valio Ltd.Inventors: Annika Mäyrä-Mäkinen, Tarja Suomalainen, Outi Vaarala
-
Publication number: 20120276201Abstract: Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants in the treatment and management of IBD.Type: ApplicationFiled: December 29, 2010Publication date: November 1, 2012Inventor: Ira Milton Trachtman
-
Publication number: 20120276054Abstract: Alternative treatments are provided for use in the inhibition, decrease, therapeutic or prophylactic support of a Bdellovibrio and like organism (BALO) Gram negative prey bacterial infection in a host.Type: ApplicationFiled: April 28, 2011Publication date: November 1, 2012Inventors: Henry N. Williams, Paul A. Gulig, Huan Chen
-
Publication number: 20120276055Abstract: The invention provides a composition that enhances the proliferation activity of propionic acid bacteria in the rumen of ruminants to allow the propionic acid bacteria to sufficiently exhibit their metabolic function in the rumen for the prevention and treatment of rumen acidosis in ruminants. The invention also provides use of the composition. Viable propionic acid bacteria and a lactic acid bacteria culture are orally administered to a ruminant to dramatically (rapidly) promote the proliferation of the propionic acid bacteria in the ruminant rumen, and to thereby increase the volatile fatty acid concentration in the rumen for the prevention and/or treatment of rumen acidosis in the ruminant.Type: ApplicationFiled: December 22, 2010Publication date: November 1, 2012Applicants: Meiji Co., Ltd., MEIJI FEED Co., Ltd.Inventors: Kenji Sera, Katsunori Kimura, Michio Kanbe, Takenori Orihashi, Manami Yoshida, Yoshiaki Obara
-
Publication number: 20120263758Abstract: The present invention encompasses pet food compositions that include one or more probiotic microorganisms, which are useful to improve the health of companion animals. For example, the invention encompasses pet food compositions including a probiotic, for example, Lactobacillus, Bifidobacterium and Streptococcus (Enterococcus). The present invention also encompasses the preparation of pet food compositions including one or more probiotic microorganisms intended for methods of maintaining or improving pet health through feeding a pet a pet food composition including the probiotic microorganism.Type: ApplicationFiled: December 18, 2009Publication date: October 18, 2012Applicant: HILL'S PET NUTRITION, INC.Inventors: Pavinee Chinachoti, Luis J. Montelongo, Christina Khoo, Kathy Lynn Gross
-
Patent number: 8277814Abstract: The present invention relates to the fields of veterinary virology and immunology. In particular the invention relates to a novel avian Astrovirus; to antibodies or fragments thereof against the novel virus; to antigenic preparations, proteins, and DNA molecules of the novel avian Astrovirus; to vaccines of the novel virus or its antigenic preparations, protein, or DNA; to methods for the manufacture of such vaccines, and to diagnostic kits.Type: GrantFiled: April 27, 2009Date of Patent: October 2, 2012Assignee: Intervet International B.V.Inventors: Sjaak De Wit, Carla Christina Schrier, Marcel Van de Laar, Iwan Verstegen
-
Publication number: 20120244124Abstract: A method of combating rheumatoid arthritis, comprising administering to a human subject in need thereof, an effective oral dose of a probiotic composition in an oral dose form including, as the only bacterial species therein, the bacterial species of Bacillus subtilis, Bacillus coagulans, and Enterococcus faecium. The initial occurrence, and progress of remission of the rheumatoid arthritis condition incident to such probiotic therapy, may be established and monitored by assay of rheumatoid factor and/or anti-CCP antibodies present in a blood sample of the human subject.Type: ApplicationFiled: June 5, 2012Publication date: September 27, 2012Applicant: COBB & ASSOCIATESInventors: Mark L. Cobb, Alyson J. Cobb
-
Publication number: 20120244125Abstract: The present invention generally relates to the field of weight management. The present invention relates for example to the use of Bifidobacterium longum ATCC BAA-999 to support weight management, promote weight loss and/or to treat obesity.Type: ApplicationFiled: September 28, 2010Publication date: September 27, 2012Applicant: NESTEC S.A.Inventors: Elena Verdu de Bercik, Premysl Bercik, Stephen Michael Collins, Gabriela Bergonzelli Degonda
-
Patent number: 8257693Abstract: The present invention provides a composition comprising prebiotic and probiotic components and is used to reduce elevated levels of nitrogenous waste products and to promote a healthy bowel microenvironment.Type: GrantFiled: March 19, 2009Date of Patent: September 4, 2012Assignee: Kibow Biotech, Inc.Inventor: Natarajan Ranganathan
-
Patent number: 8257970Abstract: The present invention provides a method for activating a Natural Killer (NK) cell by contacting the NK cell in vitro with an activating tumor cell preparation (ATCP). The invention also provides an activated NK cell produced by such a method and its use in the treatment of cancer.Type: GrantFiled: September 17, 2007Date of Patent: September 4, 2012Assignee: UCL Biomodica PLCInventor: Mark Lowdell
-
Publication number: 20120219526Abstract: The present invention relates to nutritional composition for infants and/or children comprising lactoferrin and probiotics. These compositions have been found to be useful in providing health benefits in infants and/or children. A method of manufacture of these compositions is also part of the invention. These compositions may be in the form of a kit of parts wherein a first composition according to the invention and a second composition according to the invention are each adapted to fulfil the nutritional requirements in two different age groups.Type: ApplicationFiled: October 29, 2010Publication date: August 30, 2012Applicant: Nestec S.A.Inventors: Petra Gerda Klassen, Corinne Magliola, Daniel Roland Manser, Theresa Voss
-
Publication number: 20120216304Abstract: Engineered human tissue constructs are provided that are suitable for use in making humanized animals for use in pharmaceutical development. Humanized animals having the constructs implanted in vivo are provided. Methods of making and using the tissue-engineered constructs and humanized animals are also provided.Type: ApplicationFiled: October 6, 2011Publication date: August 23, 2012Inventors: Sangeeta N. BHATIA, Alice A. CHEN, Shengyong Ng
-
Patent number: 8246946Abstract: A method for treatment or prophylaxis of a bipolar disorder disease state, by administration of an anti-fungal composition that includes at least one of the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium.Type: GrantFiled: September 27, 2006Date of Patent: August 21, 2012Assignee: Cobb & AssociatesInventors: Mark L. Cobb, Alyson Cobb
-
Publication number: 20120207712Abstract: The present invention relates to compositions comprising probiotic and prebiotic components, mineral salts, lactoferrin, and possibly saccharomycetes, which perform correct, effective colonisation of the probiotic components administered, with enteric consequences which involve maintaining and/or restoring intestinal health and preventing the consequences of common dysbioses of the digestive tract caused by stress, incorrect dietary habits and antibiotic treatments. Said compositions also have a concomitant anti-inflammatory and immunomodulating action.Type: ApplicationFiled: July 11, 2011Publication date: August 16, 2012Applicant: Pfizer Italia S.r.l.Inventors: Valeria Longoni, Marisa Penci
-
Publication number: 20120201890Abstract: The present invention generally relates to methods, compositions and uses thereof for enhancing vascularization of a tissue or cell transplant for transplantation into a subject. In particular, one aspect of the present invention provides methods and compositions comprising the use of a population of stromal vascular fraction (SVF) cells to encapsulate or surround a tissue or cell transplant to enhance vascularization of the tissue or cell transplant. Another aspect of the present invention provides methods and compositions for enhancing vascularization of a tissue or cell transplant by combining a population of SVF cells with a tissue or cell transplant to form a transplant mixed with SVF cells. In some embodiments, the SVF cells can be on the surface or embedded within a three-dimensional matrix. In some embodiments, the SVF cells can be generically engineered to secrete therapeutic proteins or pro-angiogenic factors.Type: ApplicationFiled: October 13, 2010Publication date: August 9, 2012Applicant: University of Louisville Research Foundation, Inc.Inventors: Stuart K. Williams, James Beatly Hoying, Laxminarayanan Krishnan
-
Publication number: 20120183505Abstract: Artificial dermis (1) obtained from plasma with platelets (2) and human fibroblasts. The plasma with platelets (2) is obtained from the fractionating of total blood (4) from the patient (8) by light centrifugation, and the human fibroblasts (3) from a skin biopsy, (5). Clotting is obtained by adding calcium. This artificial dermis (1) permits rapid growth of the keratinocytes (6) seeded on its surface to build an artificial skin (7) which can easily be transplanted. Large areas of artificial dermis (1) are obtained from small amounts of starting materials and can be enriched with cytokines and platelet growth factors, to strengthen proliferation of the cells seeded. The artificial skin (7) obtained can be used to treat major burn treatments, chronic skin ulcers, etc., or be used, by employing genetically altered cells, as a vehicle for gene therapy.Type: ApplicationFiled: February 7, 2012Publication date: July 19, 2012Inventors: Jose Luis Jorcano Noval, Fernando Larcher Laguzzi, Alvaro Meana Infiesta, Sara Gomez Llanes, Marcela Del Rio Nechaevsky
-
Publication number: 20120183504Abstract: A use of probiotic strain GM-263 (ADR-1) in treating renal fibrosis in diabetes is disclosed. The probiotic strain such as Lactobacillus renteri strain GM-263 (ADR-1) (accession No. CCTCC M 209263) is utilized to produce a composition for treating renal fibrosis in diabetes in an effective dose, thereby reducing the concentration of glycated hemoglobin and blood sugar and keeping body weight and kidney weight within normal range, as well as specifically inhibiting phosphorylation of JAK2/STAT1 signal transduction pathway and renal fibrosis-related protein expression.Type: ApplicationFiled: January 14, 2011Publication date: July 19, 2012Inventors: Ying-Chen LU, Jau-Shyang HUANG, Feng-Ching HSIEH, Yi-Cheng LI, Chia-Lin LEE
-
Patent number: 8216819Abstract: The present invention relates to a method for the production of onolytic adenoviruses having increased potency and their therapeutic applications for cancer. Recombinant adenoviruses and methods to produce them are provided.Type: GrantFiled: December 20, 2007Date of Patent: July 10, 2012Assignee: PsiOxus Therapeutics LimitedInventors: Terry Hermiston, Irene Kuhn
-
Publication number: 20120171161Abstract: Provided herein are compositions comprising placental stem cells and platelet rich plasma. Also provided herein are methods of treating an individual suffering from a disease or condition that would benefit from reduced inflammation, promotion of angiogenesis, and enhanced healing, comprising administering a therapeutically effective amount of a composition comprising placental stem cells and platelet rich plasma, as described herein, to said individual in an amount and for a time sufficient for detectable improvement of said disease or condition.Type: ApplicationFiled: December 29, 2011Publication date: July 5, 2012Inventors: Sascha Abramson, Mohit B. Bhatia, Uri Herzberg
-
Publication number: 20120171162Abstract: The use of at least one sulphur-containing amino acid, at a total concentration of about 5 to 75 mg/ml, in particular of about 5 to about 50 mg/l, in particular of about 5 to about 30 mg/l, in particular of about 5 to about 20 mg/l, in free form, for implementing a method for preparing a fermented food product fermented by ferments containing bifidobacteria, the food product has acceptable sensory properties, contains more than about 5×107, in particular more than about 108 bifidobacteria per gram of food product fermented for a shelf lifetime of at least 30 days, in particular a shelf lifetime of at least 35 days, and containing no more than 0.5% of yeast extract or of yeast autolysate.Type: ApplicationFiled: March 9, 2012Publication date: July 5, 2012Applicant: COMPAGNIE GERVAIS DANONEInventors: Luc TERRAGNO, Francois DEBRU, Phillippe TESSIER, Stéphane HERVE, Jean-Michel FAURIE
-
Patent number: 8206701Abstract: The present invention relates to semi-allogeneic antigen-presenting cells into which proteins and/or peptides or RNA or DNA or cDNA, respectively, encoding said proteins and/or peptides which are overexpressed in tumor cells or which are derived from autologous tumor cells or different tumor cells or different tumor cell lines have been introduced. Furthermore the invention relates to methods for the generation of these semi-allogeneic antigen-presenting cells as well as to the use thereof in the treatment of tumor diseases.Type: GrantFiled: September 16, 2003Date of Patent: June 26, 2012Assignee: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)Inventors: Dolores Schendel, Rudolf Wank
-
Publication number: 20120156171Abstract: The invention relates to a cosmetic and/or dermatological topical composition, of particular use for the preventional and/or treatment of sensitive and/or dry skin, comprising an effective amount of at least one particularly probiotic microorganism and/or a fraction or metabolite thereof in combination with an effective amount of at least one polyunsaturated fatty acid and/or polyunsaturated fatty acid ester and/or a salt or derivative thereof in a physiologically-acceptable vehicle.Type: ApplicationFiled: December 19, 2011Publication date: June 21, 2012Applicants: NESTEC S.A., L'OREALInventors: Lionel BRETON, Roland JOURDAIN, Audrey GUENICHE, Isabelle BUREAU-FRANZ, Mathilde FLEITH, Armand MALNOE
-
Publication number: 20120156649Abstract: Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.Type: ApplicationFiled: December 14, 2011Publication date: June 21, 2012Inventors: William J. Golden, Randall G. Rupp
-
Patent number: 8192733Abstract: A probiotic composition including the bacilli (1) Bacillus subtilis, (2) Bacillus coagulans, and (3) Enterococcus faecium. The composition may further include a carrier medium, such as fructo-oligo-saccharides (FOS), as incorporated in a dose form such as a pill, capsule, powder or sachet. The compositions of the disclosure may be usefully employed as health or nutritional supplements, food additives, or therapeutic agents for combating a wide variety of physiological disorders, such as irritable bowel syndrome, autism, and fibromyalgia.Type: GrantFiled: July 20, 2010Date of Patent: June 5, 2012Assignee: Cobb & AssociatesInventors: Mark L. Cobb, Alyson Cobb
-
Publication number: 20120134963Abstract: Provided are viral sensitizing compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the cytotoxicity of virus to cells. Other uses, compositions and methods of using same are also provided.Type: ApplicationFiled: July 7, 2010Publication date: May 31, 2012Applicant: Ottawa Hospital Research InstituteInventors: John Bell, Jean-Simon Diallo
-
Publication number: 20120134962Abstract: Disclosed is a method of treating a wound comprising applying a composition to a wound site on a patient in need of wound treatment, wherein the composition comprises mitotically inactive allogeneic cells that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, and wherein the cells are keratinocytes or fibroblasts, or mixtures thereof.Type: ApplicationFiled: February 8, 2012Publication date: May 31, 2012Applicant: DFB TECHNOLOGY HOLDINGS, LLCInventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20120128632Abstract: Methods for identifying trichogenic dermal cells, including dermal papilla cells and dermal sheath cells, capable of inducing hair follicle formation when injected into skin are provided. It has been discovered that EGF latrophilin and seven transmembrane domain-containing protein 1 (ELTD1). Transmembrane Protein 108 (TMEM1 08), Hyaluronan and proteoglycan link protein 1 (HAPLN1) are biomarkers that can be used to detect, identify, and distinguish trichogenic dermal cells, i.e., that are able to induce hair follicle formation, from other skin cells. Populations of skin cells enriched with trichogenic dermal cells can be produced by selecting for and enriching for dermal cells that express ELTD1, TMEM1 08, HAPLN1, or a combination thereof.Type: ApplicationFiled: July 22, 2010Publication date: May 24, 2012Inventors: Jeffrey Keeler Teumer, Vladimir Mastyugin, Jizeng Qiao, Agatha Zawadzka
-
Patent number: 8182805Abstract: The present invention relates to prevention and treatment of allergic sensitization and diseases associated therewith by treatment with an enterovirus vaccine, wherein the enterovirus does not contain an exogenous nucleic acid sequence that is integrated into the viral genome and that encodes an allergen that induces said allergic sensitization.Type: GrantFiled: January 31, 2008Date of Patent: May 22, 2012Assignee: Vactech OyInventors: Hanna Viskari, Mikael Knip, Tapio Seiskari, Heikki Hyöty, Laura Kummola, Anita Kondrashova
-
Publication number: 20120114608Abstract: Disclosed herein are compositions for treating a respiratory condition, preferably by enhancing immune response in a mammal, the compositions including a therapeutic amount of a probiotic strain of bacteria and a therapeutic amount of an additional component. Also included are methods of treating a respiratory condition, preferably by enhancing immune response, in a mammal. Kits containing the compositions, and instructions for applying the methods are also included. The method includes orally administering to the mammal a therapeutic amount of a probiotic strain of bacteria and a therapeutic amount of an additional component.Type: ApplicationFiled: December 22, 2011Publication date: May 10, 2012Inventors: James Patrick Ebel, Lucy Anne Gildea, David Alexander Lawson, Jeffrey Warren Clymer
-
Publication number: 20120114609Abstract: The present invention regards a biological material comprising: a) a liquid carrier comprising a viscous solution containing at least one natural and/or semisynthetic polysaccharide, and having a Dynamic viscosity measured at 20° C. and at shear rate of D=350 s?1, comprised between 100 and 250 c Poise and/or a Kinematic viscosity comprised between 99 and 248cSt (measured at the same conditions); b) a culture of mesenchymal stem cells, and/or c) a platelet-rich hemo-derivative. This type of material in form of viscous liquid is particularly suitable for the therapy of osteoarthrosis, ligament damage, in particular tendon and cartilage damage) and may be administered intra-articularly, intradermally or directly applied in situ without altering the properties of the mesenchymal stem cells and/or platelets contained therein.Type: ApplicationFiled: June 29, 2010Publication date: May 10, 2012Applicant: FIDIA FARMACEUTICI S.p.A.Inventors: Lanfranco Callegaro, Anna Maria Zanellato
-
Patent number: 8168201Abstract: The present invention relates to compositions for inducing immune responses, including an antigen and a promiscuous T-cell epitope. Also provided are methods of inducing immune responses in hosts, comprising administering compositions comprising antigens and promiscuous T-cell epitopes to the host.Type: GrantFiled: April 3, 2007Date of Patent: May 1, 2012Assignee: Pfizer Canada Inc.Inventors: Leslie Hickle, Abraham Anderson, Robert C. Brown, Paul Budworth, Gordana Djordjevic, Scott Kroken, Peter Luginbuhl, Toby Richardson, Genevieve Hansen
-
Publication number: 20120100108Abstract: The present invention provides methods for treating critical limb ischemia (CLI), including increasing wound healing, decreasing wound size, increasing survival-free amputation, preventing amputation, preventing or delaying de novo gangrene, increasing survival probability, and preventing or delaying death, in subjects who prevent a vascular occlusion that cannot be resolved by using a standard method of revascularization, i.e. a subject with “no-option” CLI.Type: ApplicationFiled: June 10, 2011Publication date: April 26, 2012Applicant: Aastrom Biosciences, Inc.Inventors: Ronnda Bartel, Sharon Watling
-
Publication number: 20120093779Abstract: A complex microbial preparation comprises (in vol. %): Photosynthetic bacterium (5-15%), Bacillus (10-20%), Yeasts (20-35%), Lactobacillus (30-45%) and Actinomycetes (3-10%). The preparative method of the complex microbial preparation involves first and second level complex fermentations. The first level complex fermentation involves: (a) separately inoculating the above-mentioned bacteria on first level culture media and culturing to obtain first level bacteria, (b) separately inoculating the obtained first level bacteria on second level culture media and culturing to obtain fermenting bacterial liquids, (c) mixing the five obtained fermenting bacterial liquids to obtain first level compound bacteria.Type: ApplicationFiled: November 3, 2010Publication date: April 19, 2012Inventor: Liping Wang
-
Patent number: 8142772Abstract: This invention is directed to therapeutic compositions containing non-MHC-restricted Tcells/NK-cells in combination with MHC-restricted T-cells and especially to therapeutic compositions, which comprise LAK cells. Furthermore, the present invention is directed to the use of the above combination in the treatment of tumors in humans, which tumors show a missing, low or aberrant expression of MHC class Ia or Ib molecules. By using the aforementioned compositions/combinations it is possible to provide a balanced selective pressure against emergence of tumor cell variants that would otherwise escape immune detection.Type: GrantFiled: April 22, 2010Date of Patent: March 27, 2012Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)Inventors: Elfriede Noessner, Elisabeth Weiss, Dolores Schendel, Christine Falk
-
Patent number: 8137718Abstract: The present invention is directed to an infant formula or children's nutritional product comprising a protein source, a fat source, a carbohydrate source, and B. longum AH1205.Type: GrantFiled: September 19, 2008Date of Patent: March 20, 2012Assignee: Mead Johnson Nutrition CompanyInventors: William Michael Russell, Michael Ceddia
-
Patent number: 8137662Abstract: The subject invention pertains to tumor cell lines useful for increasing the proliferation potential of any human or animal cell in culture, thereby providing immortalized or continuous cell lines and cultures. The invention also concerns proliferation factors, and compositions containing the factors, which are capable of increasing the proliferation potential of any human or other animal cell in culture. The subject invention further pertains to a method for proliferating cells in culture by containing cells with the proliferation factors. The proliferated cells can range in plasticity and can include, for example, blast cells, fertilized ova, non-fertilized gametes, embryonic stem cells, adult stem cells, precursor or progenitor cells, and highly specialized cells. Optionally, the cells can be induced to cease proliferation.Type: GrantFiled: October 31, 2007Date of Patent: March 20, 2012Assignees: University of South Florida, University of ChileInventors: Thomas B. Freeman, Pablo Caviedes, Raul Caviedes
-
Publication number: 20120052045Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs. The invention is further directed to methods of increasing time to ischemic injury in tissues and organs. Such methods utilize compositions comprising cells capable of modulating inflammatory responses, referred to herein as Inflammatory Response Modulating Cells (IRMCs). The IRMCs any be used directly or cell membranes derived from them may be used in practicing the methods of the invention. In addition, the IRMCs and IRMC membranes may be used alone or in combination with each other and/or in combination with various suitable active agents.Type: ApplicationFiled: August 25, 2011Publication date: March 1, 2012Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp
-
Publication number: 20120052047Abstract: A use of probiotic strain GM-080 in treating cardiac inflammation and apoptosis is disclosed. The probiotic strain GM-080 such as Lactobacillus paracasei strain GM-080 (accession No. CCTCC M 204012) is utilized to produce a composition for treating cardiac inflammation and apoptosis in an effective dose.Type: ApplicationFiled: November 17, 2010Publication date: March 1, 2012Applicant: GenMont Biotech IncorporationInventors: Ying-Chen LU, Feng-Ching HSIEH, Cheng-Chih TSAI, Chih-Yang HUANG, Hsueh-Fang WANG, Chien-Yu TSENG
-
Publication number: 20120039852Abstract: The present invention generally relates to the field of weight management and obesity. In particular the present invention relates to the use of probiotics in combination with prebiotics to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus rhamnosus NCC 4007 in combination with a specific probiotic mixture for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.Type: ApplicationFiled: February 4, 2010Publication date: February 16, 2012Applicant: NESTEC S.A.Inventors: Christian Darimont-Nicolau, David Philippe, Catherine Mace, Fabrizio Arigoni
-
Publication number: 20120034190Abstract: The invention is directed to isolated microorganisms, as well as biomasses, cultures, microbial oils, and compositions thereof. The invention also provides methods of producing the microbial oils and methods of using the isolated microorganisms, biomasses, and microbial oils.Type: ApplicationFiled: March 11, 2011Publication date: February 9, 2012Inventors: Kirk E. APT, William R. BARCLAY, Paul Warren BEHRENS
-
Publication number: 20120027728Abstract: The present invention provides an adjunctive agent and a method for lavaging the alimentary canal, which is able to reduce a dose of oral cleaning agent for lavaging the alimentary canal and is capable of realizing an excellent cleaning effect at the time of use of the oral cleaning agent. The adjunctive agent comprises butyric acid bacterium (for example, Clostridium butyricum and the like) and/or lactic acid bacterium (for example, species belonging to the genus Lactobacillus and the genus Bifidobacterium).Type: ApplicationFiled: October 4, 2011Publication date: February 2, 2012Applicant: MIYARISAN PHARMACEUTICAL CO., LTD.Inventors: Shinji Kumagai, Mamoru Tanaka
-
Publication number: 20120020925Abstract: The invention relates to products, processes, and therapeutic methods for restoring blood flow to tissues at risk of becoming or being ischemic by inducing angiogenesis and/or vasculogenesis in tissues in need thereof by administering endothelial colony forming cells alone or in combination with other cell types and/or agents. In one aspect, the invention is useful for inducing angiogenesis and/or vasculogenesis in patients with ischemic disease including ischemic heart disease, and other ischemic vascular disorders.Type: ApplicationFiled: February 3, 2010Publication date: January 26, 2012Inventors: Robert I. Grove, Christine Smith-Steinhart, Paul A. Hyslop
-
Patent number: 8101170Abstract: The invention relates to a probiotic health or fitness promoting human or animal foodstuff and/or drinking water additive, comprising a mixture of microorganisms, selected from the group Enterococcus faecium, DSM 16211, Lactobacillus reuteri, DSM 16350, Lactobacillus salivarius ssp. salivarius, DSM 16351, Pediococcus acidilactici, DSM 16210, Bifidobacterium animalis and DSM 16284. The invention further relates to a use of the human or animal foodstuff and/or drinking water additive, in particular for prevention of the harmful effect of a number of undesirable germs in the digestive system of animals and/or domestic birds.Type: GrantFiled: June 14, 2006Date of Patent: January 24, 2012Assignee: Erber AktiengesellschaftInventors: Regina Plail, Gerd Schatzmayr, Eva Maria Binder, Michaela Mohnl, Alfred Klimitsch, Sabine Nitsch, Viviana Klose
-
Publication number: 20120014921Abstract: This invention relates to methods of treating stroke by intranasal administration of umbilical cord tissue-derived cells, which are isolated from mammalian umbilical cord tissue substantially free of blood or expanded in culture from a cell isolated from mammalian umbilical cord tissue substantially free of blood, are capable of self-renewal and expansion in culture, and do not produce CD117 and/or telomerase. The methods of the invention regenerate, repair and improve neural tissue and improve behavior and neurological function in stroke patients.Type: ApplicationFiled: July 15, 2011Publication date: January 19, 2012Applicant: Advanced Technologies and Regenerative Medicine, LLCInventors: Brian C. Kramer, Anthony J. Kihm
-
Patent number: 8097244Abstract: Combinations of cell lines are provided for allogeneic immunotherapy agents in the treatment of cancer. Cancer vaccines generally have been limited to the use of cells that contain at least some tumor specific antigens (“TSAs”) and/or tumor associated antigens (“TAAs”) having shared identity with antigens in a targeted tumor. In such cases, tumor cells often are utilized as a starting point on the premise that only tumor cells will contain TSAs or TAAs or relevance, and the tissue origins of the cells are matched to the tumor site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells, in combination with primary and/or metastatic tumor cells, as the basis of an allogeneic cell cancer vaccine. Normal cells do not posses TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines when administered in combination with primary and/or metastatic tumor cells.Type: GrantFiled: September 8, 2008Date of Patent: January 17, 2012Assignee: Onyvax LimitedInventors: Angus George Dalgleish, Anthony Ian Walker
-
Publication number: 20120009155Abstract: Sunflower lecithin or sunflower lecithin with oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or, where they are to be combined with probiotics in a carrier, they can preferably be adsorbed to carriers to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.Type: ApplicationFiled: July 19, 2011Publication date: January 12, 2012Inventors: Randolph S. Porubcan, Sonja Lea Yonak
-
Publication number: 20120009154Abstract: Sunflower lecithin or sunflower lecithin with oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or, where they are to be combined with probiotics in a carrier, they can preferably be adsorbed to carriers to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.Type: ApplicationFiled: July 11, 2011Publication date: January 12, 2012Inventors: Randolph S. Porubcan, Sonja L. Yonak